38 results about "Leukemia lymphoma" patented technology

The invention belongs to the technical field of antibody medicines and provides two types of antibody compositions including CD45 antibody, CD13 antibody, CD33 antibody and CD7 antibody or including CD45 antibody, CD117 antibody, CD34 antibody and CD19 antibody. The invention further provides a leukemia and lymphoma typing kit comprising the two types of antibody compositions and capable of being used with a flow cytometry to achieve typing of various hematological neoplasms.

Cancers, particularly solid tumors (e.g., breast, lung, renal, colon and ovarian cancers and melanomas) and cancers of the hematologic system, e.g., hemopoietic cancers such as leukemias, lymphomas or myelomas, are treated by administration of a therapeutically effective amount of a compound having the formula (1): (I)in which the quinoline ring is substituted by from one to three groups selected from halogen and trifluoromethyl (designated in the formula by “A”), and is optionally further substituted by one or more other moieties and R is (a) NR1R2 in which R1 and R2 are independently hydrogen or C1-C4 alkyl; (b) 2-piperidyl, (c) 2-pyridyl, and (d) 5-(ethyl or vinyl)-quinuclidin-4-yl; an enantiomer of such a compound; a pharmaceutically acceptable salts of such a compound or of an enantiomer thereof; a prodrug of such a compound or of an enantiomer thereof; a metabolite of such a compound or of an enantiomer thereof; and mixtures of two or more of the foregoing. A particularly preferred compound is mefloquine.

The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia / lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.

The present invention proposes a compound represented by formula (I) or a pharmaceutically acceptable salt or prodrug thereof. The compound has a novel structure, high efficiency and low toxicity, and has excellent CXCR4 antagonistic activity, which can block HIV from invading and infecting human target cells or treat or prevent AIDS or mobilize human bone marrow hematopoietic cells, mesenchymal stem cells and stem cells or interfere with CXCL12 / CXCR4-mediated Cell migration and adhesion or prevention, treatment of tumor metastasis, invasion and growth mediated by CXCR4 or block CXCL12 / CXCR4 mediated autoimmunity and inflammatory response; and this type of compound can be used as an effective drug in the pharmaceutical composition The components can be used in combination with other anti-HIV drugs to prevent and treat HIV or in combination with other drugs used for treatment or prevention of leukemia, lymphoma, myeloma and solid tumors to prevent and treat tumors.

The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.

The invention belongs to the technical field of antibodies, and provides an antibody composition composed of ten antibodies, wherein the tan antibodies comprises CD71 resistant antibody, CD7 resistant antibody, CD13 resistant antibody, CD33 resistant antibody, CD19 resistant antibody, CD117 resistant antibody, CD34 resistant antibody, CD10 resistant antibody, HLA-DR resistant antibody, and CD45 resistant antibody. The invention provides a leukemia-lymphomas primary screening kit containing the antibodies, and the application thereof.

The invention provides a kit for detecting lymphoid blood cancers (such as T / B lineage leukemia, lymphoma, myeloma minimal residual disease) developed based on high-throughput sequencing, the kit includes detecting IGH (VDJ), IGH (DJ), IGK, IGL, TCRβ, TCRγ, TCRδ, BCL1 / IGH, BCL2 / IGH multiplex PCR primer set with UMB (Unique Molecular Barcode, single molecule tag), House Keeping gene PCR primer pair, Multiplex PCR Mix (2X), internal reference DNA, Nuclease‑Free Water, Elution Buffer, and primers and index sequences required for high-throughput sequencing. Using the kit, newly mutated cancer cells can be found while detecting cancer cells, and by applying high-throughput sequencing technology combined with bioinformatics analysis, the detection sensitivity of MRD can detect at least one cancer cell in 1 million cells , which is 10 ‑6 (0.0001%), not only can quantitatively analyze the number of cancer cells to achieve the purpose of minimal residual disease detection, but also can correct sequence mutations caused by base mismatches generated by PCR amplification and sequence reading errors generated during library sequencing.

The invention relates to an application of beta-As4S4 in preparation of a medicine for treating hematological malignant tumors. The hematological malignant tumors are selected from leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, refractory anemia with increased immature cells, and refractory anemia during conversion into leukemia. The beta-As4S4 is stable and controllable in quality and can be wetted by water, and the wettability is superior to that of natural realgar. Meanwhile, compared with natural realgar, beta-As4S4 has better dissolubility in pure water and human gastrointestinal fluid, and has a better apoptosis induction effect on hematological malignant tumor cells.